Your browser doesn't support javascript.
loading
Rituximab as an effective therapeutic option in refractory Neuro-Behçet syndrome.
Garcia-Estrada, Christian; Casallas-Vanegas, Adriana; Zabala-Angeles, Indhira; Gomez-Figueroa, Enrique; Rivas-Alonso, Verónica; Flores-Rivera, José.
Afiliación
  • Garcia-Estrada C; Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. Electronic address: christianalan.cg@gmail.com.
  • Casallas-Vanegas A; Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
  • Zabala-Angeles I; Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
  • Gomez-Figueroa E; Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
  • Rivas-Alonso V; Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
  • Flores-Rivera J; Multiple sclerosis and Demyelinating disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico; Head of Neurology Department National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
J Neuroimmunol ; 346: 577308, 2020 Jun 26.
Article en En | MEDLINE | ID: mdl-32619893
INTRODUCTION: Behçet's disease (BD) is an inflammatory disease of unknown etiology with periods of relapses and remissions. Neuro-Behçet syndrome (NBS) is one of the main causes of long-term morbidity and mortality, making its prompt recognition and early treatment fundamental to achieving a better outcome. Currently there are no treatment guidelines either for BS or NB, making the management of these patients particularly difficult. CASE PRESENTATION: We present the case report of a patient with pseudo-tumoral lesion and myelitis refractory to steroids and cyclophosphamide who successfully showed remission after treatment with an anti-CD20 therapy. CONCLUSION: This is the first report of concomitant pseudo-tumoral lesion and myelitis secondary to BS. We found rituximab treatment to be a safe and effective therapeutic option for NB supported by the radiological and clinical improvement achieved in our patient.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: J Neuroimmunol Año: 2020 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: J Neuroimmunol Año: 2020 Tipo del documento: Article Pais de publicación: Países Bajos